Lead Sponsor

Nymox Corporation

Age

45 - No limit years

Sex

MALE

Healthy Volunteers

No

•Be male aged 45 or older.
•Sign an informed consent form.
•Be in good health.
•Received NX-1207 in a previous completed study or received NX-1207 or placebo in a concurrent U.S. study (NX02-0017 and NX02-0018) and completed their V10 (365 day) visit.
•Have Prostate Gland Volume ≥ 25 mL (25 g).

•Surgery or minimally invasive surgical therapy (MIST) for treatment of BPH after first NX-1207 injection
•Post-void residual urine volume \> 200 mL
•Presence of a symptomatic median lobe of the prostate
•History of use of self-catheterization for urinary retention.
•Urinary retention in the previous 12 months.
•Prostatitis
•Urinary tract infection more than once in the past 12 months
•Prostate or bladder cancer.
•PSA ≥10 ng/mL
•Poorly controlled diabetes
•History or evidence of illness or condition that may interfere with study or endanger subject
•Participation in a study of any investigational drug (other than NX-1207) or investigational device within the previous 90 days
•Use of specific prescribed medications that may interfere with study or endanger subject